Establishment of NAFLD Cohort and Development of Fibrosis Markers
Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis
Seoul National University Boramae Hospital
1,000 participants
Jan 1, 2014
OBSERVATIONAL
Conditions
Summary
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
Eligibility
Inclusion Criteria2
- Patients with histologically confirmed fatty liver disease
- Patients with radiologically confirmed fatty liver disease
Exclusion Criteria5
- History of significant alcohol consumption
- Viral hepatitis
- Autoimmune hepatitis
- Metabolic diseases (e.g. hemochromatosis, M. Wilson, alpha 1-antitrypsin deficiency)
- Hepatotoxic medication (e.g. amiodarone)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
Transient elastography will be performed for evaluate fibrosis of liver.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02206841